The NIH Toolbox Cognitive Battery for intellectual disabilities

Three preliminary studies and future directions

David R Hessl, Stephanie M. Sansone, Elizabeth Berry-Kravis, Karen Riley, Keith F. Widaman, Leonard J Abbeduto, Andrea Schneider, Jeanine Coleman, Dena Oaklander, Kelly C. Rhodes, Richard C. Gershon

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Recent advances in understanding molecular and synaptic mechanisms of intellectual disabilities (ID) in fragile X syndrome (FXS) and Down syndrome (DS) through animal models have led to targeted controlled trials with pharmacological agents designed to normalize these underlying mechanisms and improve clinical outcomes. However, several human clinical trials have failed to demonstrate efficacy of these targeted treatments to improve surrogate behavioral endpoints. Because the ultimate index of disease modification in these disorders is amelioration of ID, the validation of cognitive measures for tracking treatment response is essential. Here, we present preliminary research to validate the National Institutes of Health Toolbox Cognitive Battery (NIH-TCB) for ID. Methods: We completed three pilot studies of patients with FXS (total n = 63; mean age 19.3 ± 8.3 years, mean mental age 5.3 ± 1.6 years), DS (n = 47; mean age 16.1 ± 6.2, mean mental age 5.4 ± 2.0), and idiopathic ID (IID; n = 16; mean age 16.1 ± 5.0, mean mental age 6.6 ± 2.3) measuring processing speed, executive function, episodic memory, word/letter reading, receptive vocabulary, and working memory using the web-based NIH-TB-CB, addressing feasibility, test-retest reliability, construct validity, ecological validity, and syndrome differences and profiles. Results: Feasibility was good to excellent (≥80 % of participants with valid scores) for above mental age 4 years for all tests except list sorting (working memory). Test-retest stability was good to excellent, and convergent validity was similar to or better than results obtained from typically developing children in the normal sample for executive function and language measures. Examination of ecological validity revealed moderate to very strong correlations between the NIH-TCB composite and adaptive behavior and full-scale IQ measures. Syndrome/group comparisons demonstrated significant deficits for the FXS and DS groups relative to IID on attention and inhibitory control, a significant reading weakness for FXS, and a receptive vocabulary weakness for DS. Conclusions: The NIH-TCB has potential for assessing important dimensions of cognition in persons with ID, and several tests may be useful for tracking response to intervention. However, more extensive psychometric studies, evaluation of the NIH-TCB's sensitivity to change, both developmentally and in the context of treatment, and perhaps establishing links to brain function in these populations, are required to determine the true utility of the battery as a set of outcome measures.

Original languageEnglish (US)
Article number35
JournalJournal of Neurodevelopmental Disorders
Volume8
Issue number1
DOIs
StatePublished - Sep 6 2016

Fingerprint

Fragile X Syndrome
Intellectual Disability
Down Syndrome
National Institutes of Health (U.S.)
Vocabulary
Executive Function
Short-Term Memory
Reproducibility of Results
Reading
Episodic Memory
Psychological Adaptation
Disabled Persons
Psychometrics
Cognition
Language
Animal Models
Biomarkers
Outcome Assessment (Health Care)
Direction compound
Clinical Trials

Keywords

  • Assessment
  • Cognition
  • Down syndrome
  • FMR1 gene
  • Fragile X syndrome
  • Outcome measures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine
  • Clinical Neurology
  • Cognitive Neuroscience

Cite this

The NIH Toolbox Cognitive Battery for intellectual disabilities : Three preliminary studies and future directions. / Hessl, David R; Sansone, Stephanie M.; Berry-Kravis, Elizabeth; Riley, Karen; Widaman, Keith F.; Abbeduto, Leonard J; Schneider, Andrea; Coleman, Jeanine; Oaklander, Dena; Rhodes, Kelly C.; Gershon, Richard C.

In: Journal of Neurodevelopmental Disorders, Vol. 8, No. 1, 35, 06.09.2016.

Research output: Contribution to journalArticle

Hessl, DR, Sansone, SM, Berry-Kravis, E, Riley, K, Widaman, KF, Abbeduto, LJ, Schneider, A, Coleman, J, Oaklander, D, Rhodes, KC & Gershon, RC 2016, 'The NIH Toolbox Cognitive Battery for intellectual disabilities: Three preliminary studies and future directions', Journal of Neurodevelopmental Disorders, vol. 8, no. 1, 35. https://doi.org/10.1186/s11689-016-9167-4
Hessl, David R ; Sansone, Stephanie M. ; Berry-Kravis, Elizabeth ; Riley, Karen ; Widaman, Keith F. ; Abbeduto, Leonard J ; Schneider, Andrea ; Coleman, Jeanine ; Oaklander, Dena ; Rhodes, Kelly C. ; Gershon, Richard C. / The NIH Toolbox Cognitive Battery for intellectual disabilities : Three preliminary studies and future directions. In: Journal of Neurodevelopmental Disorders. 2016 ; Vol. 8, No. 1.
@article{e79d4a9a457646ff99ca0f1d845a2cbf,
title = "The NIH Toolbox Cognitive Battery for intellectual disabilities: Three preliminary studies and future directions",
abstract = "Background: Recent advances in understanding molecular and synaptic mechanisms of intellectual disabilities (ID) in fragile X syndrome (FXS) and Down syndrome (DS) through animal models have led to targeted controlled trials with pharmacological agents designed to normalize these underlying mechanisms and improve clinical outcomes. However, several human clinical trials have failed to demonstrate efficacy of these targeted treatments to improve surrogate behavioral endpoints. Because the ultimate index of disease modification in these disorders is amelioration of ID, the validation of cognitive measures for tracking treatment response is essential. Here, we present preliminary research to validate the National Institutes of Health Toolbox Cognitive Battery (NIH-TCB) for ID. Methods: We completed three pilot studies of patients with FXS (total n = 63; mean age 19.3 ± 8.3 years, mean mental age 5.3 ± 1.6 years), DS (n = 47; mean age 16.1 ± 6.2, mean mental age 5.4 ± 2.0), and idiopathic ID (IID; n = 16; mean age 16.1 ± 5.0, mean mental age 6.6 ± 2.3) measuring processing speed, executive function, episodic memory, word/letter reading, receptive vocabulary, and working memory using the web-based NIH-TB-CB, addressing feasibility, test-retest reliability, construct validity, ecological validity, and syndrome differences and profiles. Results: Feasibility was good to excellent (≥80 {\%} of participants with valid scores) for above mental age 4 years for all tests except list sorting (working memory). Test-retest stability was good to excellent, and convergent validity was similar to or better than results obtained from typically developing children in the normal sample for executive function and language measures. Examination of ecological validity revealed moderate to very strong correlations between the NIH-TCB composite and adaptive behavior and full-scale IQ measures. Syndrome/group comparisons demonstrated significant deficits for the FXS and DS groups relative to IID on attention and inhibitory control, a significant reading weakness for FXS, and a receptive vocabulary weakness for DS. Conclusions: The NIH-TCB has potential for assessing important dimensions of cognition in persons with ID, and several tests may be useful for tracking response to intervention. However, more extensive psychometric studies, evaluation of the NIH-TCB's sensitivity to change, both developmentally and in the context of treatment, and perhaps establishing links to brain function in these populations, are required to determine the true utility of the battery as a set of outcome measures.",
keywords = "Assessment, Cognition, Down syndrome, FMR1 gene, Fragile X syndrome, Outcome measures",
author = "Hessl, {David R} and Sansone, {Stephanie M.} and Elizabeth Berry-Kravis and Karen Riley and Widaman, {Keith F.} and Abbeduto, {Leonard J} and Andrea Schneider and Jeanine Coleman and Dena Oaklander and Rhodes, {Kelly C.} and Gershon, {Richard C.}",
year = "2016",
month = "9",
day = "6",
doi = "10.1186/s11689-016-9167-4",
language = "English (US)",
volume = "8",
journal = "Journal of Neurodevelopmental Disorders",
issn = "1866-1947",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - The NIH Toolbox Cognitive Battery for intellectual disabilities

T2 - Three preliminary studies and future directions

AU - Hessl, David R

AU - Sansone, Stephanie M.

AU - Berry-Kravis, Elizabeth

AU - Riley, Karen

AU - Widaman, Keith F.

AU - Abbeduto, Leonard J

AU - Schneider, Andrea

AU - Coleman, Jeanine

AU - Oaklander, Dena

AU - Rhodes, Kelly C.

AU - Gershon, Richard C.

PY - 2016/9/6

Y1 - 2016/9/6

N2 - Background: Recent advances in understanding molecular and synaptic mechanisms of intellectual disabilities (ID) in fragile X syndrome (FXS) and Down syndrome (DS) through animal models have led to targeted controlled trials with pharmacological agents designed to normalize these underlying mechanisms and improve clinical outcomes. However, several human clinical trials have failed to demonstrate efficacy of these targeted treatments to improve surrogate behavioral endpoints. Because the ultimate index of disease modification in these disorders is amelioration of ID, the validation of cognitive measures for tracking treatment response is essential. Here, we present preliminary research to validate the National Institutes of Health Toolbox Cognitive Battery (NIH-TCB) for ID. Methods: We completed three pilot studies of patients with FXS (total n = 63; mean age 19.3 ± 8.3 years, mean mental age 5.3 ± 1.6 years), DS (n = 47; mean age 16.1 ± 6.2, mean mental age 5.4 ± 2.0), and idiopathic ID (IID; n = 16; mean age 16.1 ± 5.0, mean mental age 6.6 ± 2.3) measuring processing speed, executive function, episodic memory, word/letter reading, receptive vocabulary, and working memory using the web-based NIH-TB-CB, addressing feasibility, test-retest reliability, construct validity, ecological validity, and syndrome differences and profiles. Results: Feasibility was good to excellent (≥80 % of participants with valid scores) for above mental age 4 years for all tests except list sorting (working memory). Test-retest stability was good to excellent, and convergent validity was similar to or better than results obtained from typically developing children in the normal sample for executive function and language measures. Examination of ecological validity revealed moderate to very strong correlations between the NIH-TCB composite and adaptive behavior and full-scale IQ measures. Syndrome/group comparisons demonstrated significant deficits for the FXS and DS groups relative to IID on attention and inhibitory control, a significant reading weakness for FXS, and a receptive vocabulary weakness for DS. Conclusions: The NIH-TCB has potential for assessing important dimensions of cognition in persons with ID, and several tests may be useful for tracking response to intervention. However, more extensive psychometric studies, evaluation of the NIH-TCB's sensitivity to change, both developmentally and in the context of treatment, and perhaps establishing links to brain function in these populations, are required to determine the true utility of the battery as a set of outcome measures.

AB - Background: Recent advances in understanding molecular and synaptic mechanisms of intellectual disabilities (ID) in fragile X syndrome (FXS) and Down syndrome (DS) through animal models have led to targeted controlled trials with pharmacological agents designed to normalize these underlying mechanisms and improve clinical outcomes. However, several human clinical trials have failed to demonstrate efficacy of these targeted treatments to improve surrogate behavioral endpoints. Because the ultimate index of disease modification in these disorders is amelioration of ID, the validation of cognitive measures for tracking treatment response is essential. Here, we present preliminary research to validate the National Institutes of Health Toolbox Cognitive Battery (NIH-TCB) for ID. Methods: We completed three pilot studies of patients with FXS (total n = 63; mean age 19.3 ± 8.3 years, mean mental age 5.3 ± 1.6 years), DS (n = 47; mean age 16.1 ± 6.2, mean mental age 5.4 ± 2.0), and idiopathic ID (IID; n = 16; mean age 16.1 ± 5.0, mean mental age 6.6 ± 2.3) measuring processing speed, executive function, episodic memory, word/letter reading, receptive vocabulary, and working memory using the web-based NIH-TB-CB, addressing feasibility, test-retest reliability, construct validity, ecological validity, and syndrome differences and profiles. Results: Feasibility was good to excellent (≥80 % of participants with valid scores) for above mental age 4 years for all tests except list sorting (working memory). Test-retest stability was good to excellent, and convergent validity was similar to or better than results obtained from typically developing children in the normal sample for executive function and language measures. Examination of ecological validity revealed moderate to very strong correlations between the NIH-TCB composite and adaptive behavior and full-scale IQ measures. Syndrome/group comparisons demonstrated significant deficits for the FXS and DS groups relative to IID on attention and inhibitory control, a significant reading weakness for FXS, and a receptive vocabulary weakness for DS. Conclusions: The NIH-TCB has potential for assessing important dimensions of cognition in persons with ID, and several tests may be useful for tracking response to intervention. However, more extensive psychometric studies, evaluation of the NIH-TCB's sensitivity to change, both developmentally and in the context of treatment, and perhaps establishing links to brain function in these populations, are required to determine the true utility of the battery as a set of outcome measures.

KW - Assessment

KW - Cognition

KW - Down syndrome

KW - FMR1 gene

KW - Fragile X syndrome

KW - Outcome measures

UR - http://www.scopus.com/inward/record.url?scp=84985006737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985006737&partnerID=8YFLogxK

U2 - 10.1186/s11689-016-9167-4

DO - 10.1186/s11689-016-9167-4

M3 - Article

VL - 8

JO - Journal of Neurodevelopmental Disorders

JF - Journal of Neurodevelopmental Disorders

SN - 1866-1947

IS - 1

M1 - 35

ER -